Clinical trials: Concurrent Chemoradiotherapy
Locally Advanced Nasopharyngeal Carcinoma
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced…
- Trial name
- NCT07177443
- Testing
- Radiotherapy, Serplulimab, Cisplatin
- Where
- China
- Volunteers
- 710 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Esophageal Squamous Cell Carcinoma
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of carrelizumab plus concurrent chemoradiotherapy compared with placebo plus concurrent…
- Trial name
- NCT06048926
- Testing
- Carrelizumab, Paclitaxel injection, Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-small Cell Lung Cancer Stage III
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer
Concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage III non-small-cell lung cancer (NSCLC) (the 'PACIFIC regimen').
- Trial name
- NCT05557552
- Testing
- standar thoracic RT dose, decreased thoracic RT dose
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer Stage IIIA
Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection
The investigators hypothesized that the Neoadjuvant Chemoradiotherapy was a beneficial treatment for Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer, so we try to evaluate the security of treatment, the QoL of patients and…
- Trial name
- ZTOG-1202 (NCT01926483)
- Testing
- Neoadjuvant Chemoradiotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang Cancer Hospital
Vomiting, Nausea Post Chemotherapy
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
To evaluate the safety and efficacy of aprepitant combined with ondansetron and dexamethasone to prevent nausea and vomiting induced by Intensity-modulated Radiotherapy (IMRT) cisplatin-chemotherapy regimen in locally advanced…
- Conditions
- Vomiting, Nausea Post Chemotherapy, Head Neck Cancer
- Trial name
- NCT03572829
- Testing
- Aprepitant
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chinese Academy of Medical Sciences
Squamous Cell Carcinoma of the Head and Neck
Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection
Early detection of viable residual tumor or early neoplastic recurrence represents a real challenge in monitoring patients treated with concomitant chemoradiotherapy squamous cell carcinoma of the upper aerodigestive tract.
- Trial name
- TEPVAD (NCT02510872)
- Testing
- 18F-FDG PET combined with CT with iodinated contrast injection, 18F-FDG PET combined with CT without injection
- Where
- France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Caen
Non Small Cell Lung Cancer
Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
The combination of chemotherapy with radiotherapy remains the standard of therapy for patients with stage III NSCLC. A recent phase II study has presented encouraging data regarding the administration of docetaxel as…
- Trial name
- NCT00431613
- Testing
- Docetaxel, Gemcitabine, Carboplatin
- Where
- 10 sites in Greece
- Volunteers
- 38 people
- Sponsor
- Hellenic Oncology Research Group
Cervical Cancers
A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial
This study aims to conduct a prospective, multicenter, randomized controlled trial targeting patients with cervical cancer who have been pathologically confirmed to have lymph node metastasis after surgery.
- Trial name
- NCT06866951
- Testing
- Chemo-immunotherapy, CCRT
- Where
- China
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Head and Neck Cancer
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas.
- Trial name
- NCT00228488
- Testing
- Gefitinib
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Nasopharyngeal Carcinoma
S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with S-1 CCRT for locally advanced NPC.
- Trial name
- NCT03668366
- Testing
- S-1
- Where
- China
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Fudan University
Stage IIIC
Stereotactic Body Radiotherapy Boost Versus Simultaneous Integrated Boost to Pelvic Nodes Among Patients Receiving Radical Chemoradiation in Carcinoma Cervix
Cervical cancer is a significant cause of morbidity and mortality among women worldwide. Radiotherapy, in combination with chemotherapy or as a standalone treatment, is an effective treatment option for cervical cancer.
- Trial name
- NCT07585929
- Testing
- Stereotactic Body Radiotherapy Boost to Involved Pelvic Lymph Nodes, Standard Arm: Simultaneous Integrated Boost to involved pelvic node
- Where
- 3 sites in India
- Volunteers
- 150 people
- Sponsor
- All India Institute of Medical Sciences
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
This phase Ib/II trial studies the side effects and best way to give pembrolizumab with combination chemotherapy and radiation therapy before surgery and to see how well it works in treating adult patients with gastroesophageal…
- Conditions
- Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7
- Trial name
- NCT02730546
- Testing
- Carboplatin, Computed Tomography, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Mayo Clinic
Lung Cancer, Pneumonitis
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy.
- Conditions
- Lung Cancer, Pneumonitis, Radiation-Induced Lung Injury, Immunotherapy-Induced Pneumonitis
- Trial name
- INSPIRE-CRT (NCT06688422)
- Testing
- incentive spirometry
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Cooper Health System
Nasopharyngeal Carcinoma
Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National Comprehensive Cancer Network guideline.
- Trial name
- NCT02289807
- Testing
- Cisplatin, IMRT
- Where
- China
- Sponsor
- Sun Yat-sen University
Diffuse Intrinsic Pontine Glioma
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with…
- Trial name
- NCT04532229
- Testing
- Nimotuzumab+CRT(concurrent IMRT and TMZ)
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Cervical Cancer
Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study
Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer The purpose of this study is to…
- Trial name
- NCT00907140
- Testing
- Positron Emission Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Glioma Patients
Flubendazole Added to Standard Concurrent Chemoradiotherapy With Temozolomide in Patients With High-Grade Glioma
This study To evalute the efficacy and safety of adding flubendazole to standard concurrent chemoradiotherapy with temozolomide in patients with high grade glioma and also to evaluate DFS,OS for those patients in clinical…
- Trial name
- NCT07847476
- Testing
- Flubendazole
- Volunteers
- 122 people
- Sponsor
- Assiut University
Nasopharyngeal Cancer
Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study
Neoadjuvant chemotherapy followed by concurrent chemoradiation (CCRT) has been recommended in the treatment of locoregionally-advanced nasopharyngeal carcinoma (NPC), with docetaxel, cisplatin (DDP) and 5-fluorouracil (5-Fu)…
- Trial name
- NCT04850235
- Testing
- Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between tirilizumab combined with concurrent chemoradiation…
- Trial name
- TCRTOE (NCT06061146)
- Testing
- Arm A, Arm B
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer, Esophageal Cancer
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer…
- Conditions
- Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
- Trial name
- NCT03044613
- Testing
- Nivolumab, Relatlimab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins